New MRI technique could spot brain tumors without a biopsy

NCT ID NCT04772456

First seen Oct 31, 2025 · Last updated Jun 21, 2026 · Updated 37 times

Summary

This early-phase study tests a new MRI technique that uses a special substance called hyperpolarized pyruvate to make brain tumors easier to see. The goal is to see if this method is safe and more accurate than standard MRI for diagnosing gliomas. Up to 5 adults with suspected or known brain tumors will take part at the University of Maryland.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Rosy Njonkou Tchoquessi

    RECRUITING

    Baltimore, Maryland, 21201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Hyperpolarized 13C-Pyruvate injection

What this could lead to

If successful, this could lead to a more accurate, non-invasive way to diagnose brain tumors using MRI, potentially reducing the need for biopsies.

What could go wrong

This is a very early, small study with only 5 participants, so results may not apply to everyone. The technique is still experimental and may not prove more useful than current methods.

Conditions

The condition(s) this trial relates to.

glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.